The myeloma drug lenalidomide promotes the cereblon-dependent destruction of ikaros proteins

Science

Volumn 343, Issue 6168, 2014, Pages 305-309

  Lu, Gang ^a   Middleton, Richard E ^a   Sun, Huahang ^a   Naniong, MarkVic ^a   Ott, Christopher J ^a   Mitsiades, Constantine S ^a   Wong, Kwok Kin ^a   Bradner, James E ^a   Kaelin, William G ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA CATENIN; BORTEZOMIB; CEREBLON UBIQUITIN LIGASE; CYCLOSPORIN; DIMETHYLOXALYLGLYCINE; IKAROS FAMILY ZINC FINGER PROTEIN 1; IKAROS FAMILY ZINC FINGER PROTEIN 3; IKAROS TRANSCRIPTION FACTOR; INTERFERON REGULATORY FACTOR 4; LENALIDOMIDE; MYC PROTEIN; OXYGENASE INHIBITOR; PEVONEDISTAT; POMALIDOMIDE; RAPAMYCIN; SHORT HAIRPIN RNA; THALIDOMIDE; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG; ZINC FINGER PROTEIN;

BIOCHEMICAL COMPOSITION; CYPRINID; CYTOLOGY; DRUG; PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME SPECIFICITY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; MYELOMA CELL; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STABILITY; TERATOGENICITY;

DANIO RERIO;

EID: 84892593087     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.1244917     Document Type: Article

References (29)

1. R. Martiniani, V. Di Loreto, C. Di Sano, A. Lombardo, A. M. Liberati, Adv. Hematol. 2012, 842945 (2012).
2. E. Terpos, N. Kanellias, D. Christoulas, E. Kastritis, M. A. Dimopoulos, Onco Targets Ther 6, 531-538 (2013).
3. Y. X. Zhu, K. M. Kortuem, A. K. Stewart, Leuk. Lymphoma 54, 683-687 (2013).
4. T. Ito et al., Science 327, 1345-1350 (2010).
5. A. Lopez-Girona et al., Leukemia 26, 2326-2335 (2012).
6. L. H. Zhang et al., Br. J. Haematol. 160, 487-502 (2013).
7. Y. Yang et al., Cancer Cell 21, 723-737 (2012).
8. Y. X. Zhu et al., Blood 118, 4771-4779 (2011).
9. A. Broyl et al., Blood 121, 624-627 (2013).
10. D. Heintel et al., Br. J. Haematol. 161, 695-700 (2013).
11. G. J. Zhang et al., Nat. Med. 10, 643-648 (2004).
12. M. Safran et al., Proc. Natl. Acad. Sci. U.S.A. 103, 105-110 (2006).
13. H. C. Yen, Q. Xu, D. M. Chou, Z. Zhao, S. J. Elledge, Science 322, 918-923 (2008).
14. T. A. Soucy et al., Nature 458, 732-736 (2009).
15. M. Ohh et al., EMBO Rep. 3, 177-182 (2002).
16. L. Cong et al., Science 339, 819-823 (2013).
17. P. Mali et al., Science 339, 823-826 (2013).
18. M. Merkenschlager, FEBS Lett. 584, 4910-4914 (2010).
19. E. C. Thompson et al., Immunity 26, 335-344 (2007).
20. I. Ferreirós-Vidal et al., Blood 121, 1769-1782 (2013).
21. S. Monticelli, F. Sallusto, Nat. Immunol. 13, 719-720 (2012).
22. L. A. Garraway, W. R. Sellers, Nat. Rev. Cancer 6, 593-602 (2006).
23. S. P. Shah et al., N. Engl. J. Med. 360, 2719-2729 (2009).
24. P. Kastner et al., Am J Blood Res 3, 1-13 (2013).
25. F. J. Quintana et al ., Nat. Immunol. 13, 770-777 (2012).
26. N. Avitahl et al., Immunity 10, 333-343 (1999).
27. J. Laubach, P. Richardson, K. Anderson, Annu. Rev. Med. 62, 249-264 (2011).
28. P. G. Richardson et al., J. Clin. Oncol. 27, 5713-5719 (2009).
29. G. R. Crabtree, S. L. Schreiber, Trends Biochem. Sci. 21, 418-422 (1996).